Denne side blev automatisk oversat, og nøjagtigheden af oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

27. maj 2026 opdateret af: Exelixis

The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

5000

Fase

Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Navn: Exelixis Clinical Trials
Telefonnummer: 1-888-EXELIXIS (888-393-5494)
E-mail: druginfo@exelixis.com

Undersøgelse Kontakt Backup

Navn: Backup or International
Telefonnummer: 650-837-7400

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

Barn
Voksen
Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Key Inclusion Criteria:

Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation/withdrawal criteria).
Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.
Able to comply with the long-term extension study protocol as determined by the investigator.
Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.

Key Exclusion Criteria:

Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.
Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.
Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.
Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).
Concurrent participation in any therapeutic clinical trial (other than the parent study).

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Primært formål: Behandling
Tildeling: N/A
Interventionel model: Enkelt gruppeopgave
Maskning: Ingen (Åben etiket)

Antal våben

Våben og indgreb

Deltagergruppe / Arm	Intervention / Behandling
Eksperimentel: Cabozantinib/Zanzalintinib Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.	Medicin: Cabozantinib Administered as specified in the parent study. Andre navne: Cabometyx XL184 Medicin: Zanzalintinib Administered as specified in the parent study. Andre navne: XL092 Medicin: Atezolizumab Administered as specified in the parent study. Medicin: Nivolumab Administered as specified in the parent study. Medicin: Abiraterone Administered as specified in the parent study. Medicin: Prednisone Administered as specified in the parent study. Medicin: Enzalutamide Administered as specified in the parent study.

Deltagergruppe / Arm

Intervention / Behandling

Eksperimentel: Cabozantinib/Zanzalintinib

Depending on the study treatment received in the parent study, participants may receive cabozantinib alone or in combination with other agents; zanzalintinib alone or in combination with other agents, or comparator.

Medicin: Cabozantinib